NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis → 🚀 Tap into this explosive trade opportunity asap (From Daily Strike Alliance) (Ad) Free OCS Stock Alerts $11.90 +0.05 (+0.42%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$11.72▼$11.9550-Day Range$10.81▼$13.0752-Week Range$9.05▼$14.50Volume9,067 shsAverage Volume42,465 shsMarket Capitalization$481.95 millionP/E RatioN/ADividend YieldN/APrice Target$30.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oculis alerts: Email Address Oculis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside153.5% Upside$30.17 Price TargetShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.21 out of 5 starsMedical Sector781st out of 931 stocksPharmaceutical Preparations Industry368th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOculis has only been the subject of 4 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 16.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 2.1 News and Social Media Coverage News SentimentOculis has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oculis this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($1.84) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oculis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIThree basic steps to building the Ultimate Dividend Portfolio.There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free). About Oculis Stock (NASDAQ:OCS)Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Read More OCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesMay 24, 2024 | americanbankingnews.comHead-To-Head Review: Oculis (OCS) & The CompetitionMay 23, 2024 | finance.yahoo.comWhile institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownershipMay 22, 2024 | americanbankingnews.comCritical Analysis: Oculis (OCS) and The CompetitionMay 18, 2024 | msn.comOCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | globenewswire.comOculis updates share capital for its existing at-the-market offering programMay 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Oculis Holding (OCS)May 8, 2024 | markets.businessinsider.comOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic NeuritisMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 7, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 6, 2024 | globenewswire.comOculis to Present at Bank of America Global Healthcare ConferenceApril 29, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingApril 26, 2024 | investing.comOculis shares target cut, retains buy rating on completed equity financingApril 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Oculis Holding Ahead of Key OCS-02 Drug Data ReleaseApril 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)April 22, 2024 | finanznachrichten.deOculis Holding AG: Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 11, 2024 | globenewswire.comOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main MarketApril 10, 2024 | globenewswire.comOculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & DevelopmentApril 8, 2024 | globenewswire.comPositive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingApril 4, 2024 | globenewswire.comOculis to Participate at Upcoming April Investor ConferencesMarch 25, 2024 | msn.comOculis Holding (NASDAQ:OCS): Riding on Bullish ExpectationsMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed on Oculis Holding with Promising Clinical Pipeline and Strong Financial PositionMarch 18, 2024 | finanznachrichten.deOculis Holding AG: Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company ProgressSee More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/28/2024Next Earnings (Estimated)9/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Target$30.17 High Stock Price Target$35.00 Low Stock Price Target$24.00 Potential Upside/Downside+153.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,920,000.00 Net Margins-6,712.02% Pretax Margin-10,040.34% Return on Equity-52.72% Return on Assets-43.72% Debt Debt-to-Equity Ratio0.01 Current Ratio4.71 Quick Ratio4.71 Sales & Book Value Annual Sales$980,000.00 Price / Sales491.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book4.15Miscellaneous Outstanding Shares40,500,000Free FloatN/AMarket Cap$481.95 million OptionableNot Optionable Beta0.53 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 56)M.D., CEO & Director Ms. Sylvia Cheung (Age 49)Chief Financial Officer Dr. Ramin Tadayoni M.D.Ph.D., Chief Scientific OfficerMs. Virginia R. Dean (Age 57)Chief Human Resources Officer Dr. Bastian Dehmel M.D. (Age 53)Chief Development Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Business Officer Ms. Rebecca WeilChief Commercial OfficerDr. Snehal Shah Pharm.D.President of Research & DevelopmentMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXGalapagosNASDAQ:GLPGAgios PharmaceuticalsNASDAQ:AGIOProtagonist TherapeuticsNASDAQ:PTGXZai LabNASDAQ:ZLABView All CompetitorsInstitutional OwnershipNan Fung Group Holdings LtdSold 82,555 shares on 5/14/2024Ownership: 1.077%View All Institutional Transactions OCS Stock Analysis - Frequently Asked Questions Should I buy or sell Oculis stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCS shares. View OCS analyst ratings or view top-rated stocks. What is Oculis' stock price target for 2024? 8 brokers have issued 1-year target prices for Oculis' shares. Their OCS share price targets range from $24.00 to $35.00. On average, they anticipate the company's share price to reach $30.17 in the next twelve months. This suggests a possible upside of 153.5% from the stock's current price. View analysts price targets for OCS or view top-rated stocks among Wall Street analysts. How have OCS shares performed in 2024? Oculis' stock was trading at $11.23 at the start of the year. Since then, OCS stock has increased by 6.0% and is now trading at $11.90. View the best growth stocks for 2024 here. Are investors shorting Oculis? Oculis saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 46,000 shares, an increase of 16.8% from the April 30th total of 39,400 shares. Based on an average trading volume of 39,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the company's shares are short sold. View Oculis' Short Interest. When is Oculis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our OCS earnings forecast. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.03. The company earned $0.22 million during the quarter, compared to analysts' expectations of $0.28 million. Oculis had a negative trailing twelve-month return on equity of 52.72% and a negative net margin of 6,712.02%. Who are Oculis' major shareholders? Oculis' stock is owned by a number of institutional and retail investors. Top institutional investors include Nan Fung Group Holdings Ltd (1.08%). How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCS) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
